Chimeric Therapeutics Limited

CHIA:CHM Stock Report

Market Cap: AU$8.1m

Chimeric Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure2.8yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

CEO

Chimeric Therapeutics has no CEO, or we have no data on them.

Leadership Team

NamePositionTenureCompensationOwnership
Paul Hopper
Founder & Executive Chairman4.8yrsAU$301.98k11.41%
A$ 929.6k
Phillip Hains
CFO, Joint Company Secretary & Director4.1yrsno data1.14%
A$ 92.9k
Rebecca McQualter
Chief Operating Officerless than a yearAU$453.86kno data
Jason Litten
Chief Medical Officer2.3yrsAU$1.16mno data
Kelly Thornburg
VP & Head of Quality2.8yrsno datano data
Nathan Jong
Joint Company Secretary4.1yrsno datano data

2.8yrs

Average Tenure

63yo

Average Age

Experienced Management: CHM's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul Hopper
Founder & Executive Chairman4.8yrsAU$301.98k11.41%
A$ 929.6k
Phillip Hains
CFO, Joint Company Secretary & Director1.3yrsno data1.14%
A$ 92.9k
Larry Couture
Member of Glioblastoma Expert Advisory Boardno datano datano data
Eric Sullivan
Non-Executive Director1.3yrsAU$68.78kno data
Lesley Russell
Non-Executive Director4.3yrsAU$50.00k0.19%
A$ 15.7k
David Maloney
Member of Cellular Immunotherapy Scientific Advisory Board3.2yrsno datano data
Nader Sanai
Member of Glioblastoma Expert Advisory Boardno datano datano data
Yvonne Chen
Member of Glioblastoma Expert Advisory Board3.8yrsno datano data
Christine Brown
Chairman of Glioblastoma Expert Advisory Boardno datano data1.34%
A$ 109.5k
Yi Lin
Member of Cellular Immunotherapy Scientific Advisory Board3.3yrsno datano data
Eric Smith
Member of Cellular Immunotherapy Scientific Advisory Board3.2yrsno datano data
Michael Bishop
Member of Cellular Immunotherapy Scientific Advisory Board3.2yrsno datano data

3.2yrs

Average Tenure

65yo

Average Age

Experienced Board: CHM's board of directors are considered experienced (3.2 years average tenure).